These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 26896194)

  • 1. Donor-Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients.
    Levitsky J; Kaneku H; Jie C; Walsh RC; Abecassis M; Tambur AR
    Am J Transplant; 2016 Aug; 16(8):2437-44. PubMed ID: 26896194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leukocyte antigen compatibility and incidence of donor-specific antibodies in pediatric liver transplant recipients.
    Melere MU; Feier FH; Neumann J; Kalil AN; Montagner JM; Nader LS; da Silva CS; Junior MAF; Coral GP; Bobsin GP; Ferreira CT
    World J Gastroenterol; 2024 Sep; 30(33):3837-3845. PubMed ID: 39351427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation.
    Kim H; Yi NJ; Song EY; Lee K; Lee KW; Lee HW; Ahn HY; Yoon KC; Hong SK; Suh KS
    Clin Transplant; 2018 May; 32(5):e13244. PubMed ID: 29577436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation.
    Shaked A; Ghobrial RM; Merion RM; Shearon TH; Emond JC; Fair JH; Fisher RA; Kulik LM; Pruett TL; Terrault NA;
    Am J Transplant; 2009 Feb; 9(2):301-8. PubMed ID: 19120082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
    Ziemann M; Altermann W; Angert K; Arns W; Bachmann A; Bakchoul T; Banas B; von Borstel A; Budde K; Ditt V; Einecke G; Eisenberger U; Feldkamp T; Görg S; Guthoff M; Habicht A; Hallensleben M; Heinemann FM; Hessler N; Hugo C; Kaufmann M; Kauke T; Koch M; König IR; Kurschat C; Lehmann C; Marget M; Mühlfeld A; Nitschke M; Pego da Silva L; Quick C; Rahmel A; Rath T; Reinke P; Renders L; Sommer F; Spriewald B; Staeck O; Stippel D; Süsal C; Thiele B; Zecher D; Lachmann N
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1056-1066. PubMed ID: 31213508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.
    Kaneku H; O'Leary JG; Banuelos N; Jennings LW; Susskind BM; Klintmalm GB; Terasaki PI
    Am J Transplant; 2013 Jun; 13(6):1541-8. PubMed ID: 23721554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.
    Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JSF; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
    Am J Transplant; 2018 Sep; 18(9):2274-2284. PubMed ID: 29464832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver.
    Abu-Elmagd KM; Wu G; Costa G; Lunz J; Martin L; Koritsky DA; Murase N; Irish W; Zeevi A
    Am J Transplant; 2012 Nov; 12(11):3047-60. PubMed ID: 22947059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic benefits of maternal living donor allografts in pediatric liver transplantation: fewer rejection episodes and no evidence of de novo allosensitization.
    Barbetta A; Meeberg G; Rocque B; Barhouma S; Weaver C; Gilmour S; Faytrouni F; Guttman O; Zielsdorf S; Etesami K; Kwon Y; Yanni G; Campbell P; Shapiro J; Emamaullee J
    Pediatr Transplant; 2022 May; 26(3):e14197. PubMed ID: 34806273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De Novo Donor-Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes.
    Brooks AM; Carter V; Liew A; Marshall H; Aldibbiat A; Sheerin NS; Manas DM; White SA; Shaw JA
    Am J Transplant; 2015 Dec; 15(12):3239-46. PubMed ID: 26227015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications and Their Resolution in Recipients of Deceased and Living Donor Liver Transplants: Findings From the A2ALL Cohort Study.
    Samstein B; Smith AR; Freise CE; Zimmerman MA; Baker T; Olthoff KM; Fisher RA; Merion RM
    Am J Transplant; 2016 Feb; 16(2):594-602. PubMed ID: 26461803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
    Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
    Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative outcomes of DSA positive, crossmatch negative living donor kidney transplants versus remaining on the waitlist for an HLA compatible deceased donor.
    Santos E; Lucisano G; Dor FJMF; Willicombe M
    Transpl Immunol; 2024 Oct; 86():102098. PubMed ID: 39074764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.
    Schluckebier D; Cousin VL; Petit LM; Belli D; Wildhaber B; Rougemont AL; Villard J; Ferrari-Lacraz S; McLin VA
    Pediatr Transplant; 2020 Feb; 24(1):e13611. PubMed ID: 31682057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.
    Terrault NA; Shiffman ML; Lok AS; Saab S; Tong L; Brown RS; Everson GT; Reddy KR; Fair JH; Kulik LM; Pruett TL; Seeff LB;
    Liver Transpl; 2007 Jan; 13(1):122-9. PubMed ID: 17192908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous Immunoglobulins Alone for the Desensitization of Lung Transplant Recipients with Preformed Donor Specific Antibodies and Negative Flow Cytometry Crossmatch.
    Abdulqawi R; Alawwami M; Aldosari O; Aldosari Z; Alhuqbani M; Saleh RA; Esendagli D; Aldakhil H; De Vol EB; Alkattan K; Marquez KAH; Saleh W; Sandoqa S; Al-Mutairy EA
    Clin Transplant; 2024 Jul; 38(7):e15374. PubMed ID: 38979724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult Living Donor Versus Deceased Donor Liver Transplant (LDLT Versus DDLT) at a Single Center: Time to Change Our Paradigm for Liver Transplant.
    Humar A; Ganesh S; Jorgensen D; Tevar A; Ganoza A; Molinari M; Hughes C
    Ann Surg; 2019 Sep; 270(3):444-451. PubMed ID: 31305283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.